Abstract:Every year, Candida, Aspergillus, Cryptococcus and Pneumocystis infect an estimated two million individuals worldwide. Most are immunocompromised or critically ill. Candida is the most common fungal pathogen of the critically ill and of recipients of transplanted abdominal organs. In high-risk haemato-oncological patients, in contrast, the introduction of antifungal prophylaxis with fluconazole and later with mould-active posaconazole has led to a remarkable reduction of invasive candidiasis and is likely to have a similar effect on invasive aspergillosis. Invasive aspergillosis remains the dominant invasive fungal disease (IFD) of haemato-oncological patients and solid-organ transplant recipients and is increasingly found in individuals with exacerbated chronic obstructive pulmonary disease on corticosteroids. In the developed world, owing to antiretroviral therapy Pneumocystis pneumonia and cryptococcosis have become rare in patients with human immunodeficiency virus (HIV) and are mainly found in solid-organ transplant recipients or immunocompromised patients. In the developing world, cryptococcosis remains a common and highly lethal disease of HIV positive individuals. With invasive candidiasis and invasive aspergillosis, timely diagnosis is the principal challenge. The clinical presentation is nonspecific and current diagnostic tests lack sensitivity and specificity. The combination of several tests improves sensitivity, but not specificity. Standardised polymerase chain-reaction-based assays may be promising tools for more rapid and specific diagnosis of candidiasis and invasive aspergillosis. Nevertheless, initiation of treatment is often based solely on clinical suspicion. Empirical therapy, however, may lead to over-treatment of patients without IFD or it may miss its target in the case of resistance. Despite the success of antifungal prophylaxis in reducing the incidence of IFDs in haemato-oncological patients, there are a considerable number of breakthrough infections demonstrating not only fungal resistance but also the emergence of rare and often lethal fungal pathogens. Knowledge of the local epidemiology and antifungal resistance is therefore pivotal. Current trial-based guidelines leave major gaps in identifying those most at risk, who may benefit from prophylaxis. Ongoing searches for disease-associated genetic polymorphisms may contribute to the establishment of individual risk profiles and targeted prophylaxis.

Diagnosing fungal infections in clinical practice: a narrative review

Diagnosis of invasive fungal infections: challenges and recent developments

Fungal infections diagnosis - Past, present and future

Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches

A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?

The Species Distribution of Candidemia and the Advances on Diagnosis and Treatment

Progress on nonculture based diagnostic tests for invasive mould infection

Maximizing Yield and Speed of Fungal Pathogen Identification with Molecular Testing Performed Directly on Patient Specimens

Nucleic Acid Tools for Invasive Fungal Disease Diagnosis

Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematological malignancies

The future of novel diagnostics in medical mycology

Invasive Fungal Infection.

The Diagnosis of Invasive Fungal Diseases: Current Status and Future Perspectives

Antifungal drug resistance: do molecular methods provide a way forward?

Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: a comprehensive review

Diagnosis of invasive respiratory mycoses in the immunocompromised host

Evaluating the use of PCR for diagnosing invasive aspergillosis

Next-Generation Sequencing Applications for the Study of Fungal Pathogens

Microbiological Diagnosis of Pulmonary Aspergillus Infections

Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia

The need for fast and accurate detection of dermatomycosis